Table 1 Phase I study of DC-based therapy against melanoma
Patient No. | Age | Sex | Previous therapy | Measurable lesions | DC injection (times) | Side effect | DTH | Response | |
|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Â | Â | peptide | KLH | Â |
1 | 41 | F | ST, CT, RT, IFNβ | lung, LN | 1 × 107(10) | Hepatic (II) | - | ++ | PR |
2 | 75 | M | ST, CT, IFNβ | LN | 1 × 107(10) | - | + | + | SD |
3 | 49 | F | ST, CT, IFNβ, RT | lung, liver | 1 × 107(3) | - | - | - | (PD)* |
4 | 49 | M | ST, CT | lung, liver | 2 × 107(6) | - | - | - | PD |
5 | 50 | M | ST, CT, IFNβ | lung, liver, LN | 2 × 107(6) | Hepatic (I) | - | - | PD |
6 | 69 | M | ST, CT, IFNβ | LN | 2 × 107(10) | - | + | + | CR |
7 | 61 | M | ST, CT, RT | liver, LN | 5 × 107(8) | Hepatic (I) | + | ++ | PD |
8 | 64 | F | ST, CT, RT | lung | 5 × 107(3) | Fever (I) | - | - | (PD) |
9 | 66 | F | ST, CT, | lung, LN | 5 × 107(3) | - | - | - | (PD) |